Practical Treatment with Minimum Maintenance Dose of Anti-Thyroid Drugs for Prediction of Remission in Graves' Disease.
- 1 January 2003
- journal article
- clinical trial
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 50 (1), 45-49
- https://doi.org/10.1507/endocrj.50.45
Abstract
Although many researchers have reported clinical and laboratory parameters for prediction of remission in Graves' disease during or after anti-thyroid drug therapy, there is no reliable one to assure the complete remission. We prospectively examined a practical therapy with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves' disease. Fifty-seven patients with Graves' disease were treated with anti-thyroid drugs at the initial dose of 30 mg/day of methimazole (MMI) or 300 mg/day of propylthiouracil (PTU). Then, doses were gradually decreased, and finally discontinued when the patients were able to maintain euthyroid (normal FT4 and TSH) for at least 6 months with the minimum maintenance dose (MMI 5 mg every other day or PTU 50 mg every other day). After discontinuation of drugs, FT4, FT3, TSH and TSH-binding inhibitory immunoglobulin (TBII) were measured every one to two months for the first 6 months and every 3-4 months for the next 18 months to confirm continuous remission. After 2 years of drug cessation, 46 (81%) of 57 patients were in remission and the other 11 patients had relapsed into thyrotoxicosis. At the time of drug discontinuation, the serum concentration of FT4, FT3 and TSH, titers of anti-thyroglobulin antibodies and anti-thyroid microsomal antibodies, goiter size were not different between the remission and relapse groups. At the time of drug cessation, the activities of TBII and thyroid-stimulating antibodies (TSAb) overlapped between the two groups, although they were significantly lower in the remission group than in the relapse group (p<0.01). Forty percent (4/10) of TBII positive patients and 71% (23/32) of TSAb positive patients continued to be in remission. On the other hand, thyrotoxicosis relapsed in 5 (11%) of 47 TBII negative and 2 (8%) of 25 TSAb negative patients. These data indicate that minimum maintenance therapy to keep euthyroid (normal FT4 and TSH) for 6 months is a practical measure for 81% prediction of remission in Graves' disease. The measurement of TBII or TSAb gave little additional information for predicting remission.Keywords
This publication has 21 references indexed in Scilit:
- Remission of Graves' Hyperthyroidism Predicted by Smooth Decreases of Thyroid-Stimulating Antibody and Thyrotropin-Binding Inhibitor Immunoglobulin During Antithyroid Drug TreatmentThyroid®, 2000
- TSH Receptor Antibody Measurement in the Diagnosis and Management of Graves' Disease Is Rarely NecessarybJournal of Clinical Endocrinology & Metabolism, 1998
- Prediction of remission in Graves' disease treated with long-term carbimazole therapy: Evaluation of technetium-99m thyroid uptake and TSH concentrations as prognostic indicatorsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1996
- Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' diseaseJournal of Clinical Endocrinology & Metabolism, 1994
- Plasma Free Triiodothyronine Response to Thyrotropin-Releasing Hormone to Predict the Remission of Graves’ Disease Treated with Antithyroid Drugs*Journal of Clinical Endocrinology & Metabolism, 1991
- Antithyroid Drug Therapy for Graves' Hyperthyroidism: Is Long-Term Administration of a Small Maintenance Dose Necessary?Endocrinologia Japonica, 1991
- Serum Free Triiodothyronine to Free Thyroxine Ratio Enables Early Prediction of the Outcome of Antithyroid Drug Therapy in Patients with Graves' Hyperthyroidism.Endocrinologia Japonica, 1991
- OUTCOME OF PATIENTS WITH GRAVES' DISEASE AFTER LONG‐TERM MEDICAL TREATMENT GUIDED BY TRIIODOTHYRONINE (T3) SUPPRESSION TESTClinical Endocrinology, 1983
- Thionamide Therapy in Graves' Disease: Relation of Relapse Rate to Duration of TherapyAnnals of Internal Medicine, 1980
- Long term antithyroid drug therapy for intractable cases of graves' disease.Endocrinologia Japonica, 1978